Cavidi is the company behind Exazym®, which solves a critical research challenge: ultra-sensitive detection of low-abundance biomarkers using standard immunoassay workflows. It enables biomarker detection by amplifying immunoassay signals up to 100x with minimal background noise, allowing researchers in academic labs, biotech companies, CROs, and hospitals to detect biomarkers previously thought impossible to measure—cardiac troponins, Alzheimer's biomarkers, cytokines—without specialized equipment.
